Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Batu Biologics Inc patents


Recent patent applications related to Batu Biologics Inc. Batu Biologics Inc is listed as an Agent/Assignee. Note: Batu Biologics Inc may have other listings under different names/spellings. We're not affiliated with Batu Biologics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Batu Biologics Inc-related inventors


Prophylactic vaccine to tumor angiogenesis

Disclosed are compositions of matter, protocols, and treatment means for inducing an enhanced immunity targeting tumor endothelium in order to prophylactically protect subjects from development of neoplasia. In one embodiment, the invention provides placental endothelial cells that are tissue culture expanded under proliferative conditions to resemble the tumor endothelial driven angiogenesis. ... Batu Biologics Inc

Immunotherapy of aberrant ocular angiogenesis by placental vaccination

Disclosed are materials, methods, and protocols for inducing a therapeutic response in ocular conditions, such as diabetic retinopathy and wet macular degeneration, by immunizing with placental endothelial cells. In one embodiment, the invention teaches the administration of placental endothelial cells or products thereof, in an immunogenic context to induce antibody and/or cellular immune responses towards ocular neovascularization. ... Batu Biologics Inc

Chimeric antigen receptor targeting of tumor endothelium

Disclosed are methods, protocols, and compositions of matter related to utilization of chimeric antigen receptor (car) expressing cells for the targeting of tumor endothelium utilizing chimeric antigen receptor expressing stem cells. In one embodiment tumor endothelium specific antigens are utilized as targets of the antigen binding domain of a car, which is attached to an extracellular hinge domain, a domain that transverses the t cell membrane and an intracellular domain associated with t cell signaling. ... Batu Biologics Inc

Adjuvants useful for stimulation of immunity to tumor endothelial cells

Adjuvants acting at the level of antigen presentation useful for stimulation of specific immunity against tumor endothelial cells. In one embodiment the invention teaches the use of activation of specific antigen presenting cell programs to selectively induce cytotoxic t cells and antibodies with complement activating ability while not evoking antigenic responses that potentially stimulate angiogenesis or growth of tumor endothelial cells. ... Batu Biologics Inc

Probiotic augmentation of anti-tumor endothelium immune responses

Augmenting or stimulating an immune response, to tumor endothelial cells, by: a) obtaining a tumor endothelial antigen or composition of antigens; b) administering said tumor endothelial antigen or composition of antigens in an immunogenic manner to a host; and c) providing a probiotic and/or prebiotic mixture to said host being immunized.. . ... Batu Biologics Inc

Clinically useful non-antigen pulsed dendritic cells

Disclosed are compositions, methods of use, and pharmaceutical preparations useful for treatment of cancer. In one embodiment dendritic cells (dc) are generated from a patient in need of treatment, matured utilizing a leukocyte lysate, and readministered into the same patient without the use of antigen pulsing. ... Batu Biologics Inc

Polyvalent anti-tumor fibroblast vaccine

Compositions of matter, of production, and treatment modalities are disclosed for the prevention and/or therapeutic reduction of tumors through induction of immunity against tumor associated fibroblasts and components of tumor microenvironment. In one embodiment of the invention, placentally derived fibroblast cells are cultured under conditions replicating tumor microenvironment. ... Batu Biologics Inc

Gene edited antigen presenting cells

Disclosed are cells, compositions of matter, and protocols, useful for stimulation of antigen-specific immunity or tolerogenesis by gene editing of immune suppressive costimulatory molecules for induction of immune stimulation, and gene editing of immune stimulatory molecules for immune suppression. Provided are means of stimulating immunity to cancer, viral antigens, or bacterial antigens through pulsing, fusing, or administering antigenic compositions to antigen presenting cells that are gene silenced for immune suppressive genes. ... Batu Biologics Inc

Inactivation of lymphocyte immunological checkpoints by gene editing

Disclosed are methods, protocols, and compositions of matter useful for generation of lymphocytes with permanently inactivated immunological checkpoint genes, said genes comprising pd-1, ctla-4, lag-3, and tim-3. The generated lymphocytes may be autologous or allogeneic, and are useful in the treatment of neoplastic, viral or bacterial infections.. ... Batu Biologics Inc

Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer

The current invention provides monocytic cells transfected with chimeric antigen receptor (car) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. ... Batu Biologics Inc

Dna nanoparticle based checkpoint inhibitors

The invention discloses the utilization of dna generated nanoparticles to block interaction between inhibitory signals in immune cells. Provided are compositions of matter, protocols and treatment methodologies for stimulation immunity through inhibiting suppressive molecules through the use of dna based nanoparticles.. ... Batu Biologics Inc

Amplification of epitope specific personalized anti-angiogenic immune responses

Disclosed are therapeutic means, protocols, and compositions of matter useful for treatment of cancer by eliciting and amplifying immune responses specific to antigens found on tumor endothelium. In one embodiment of the invention a patient is immunized with a polyvalent anti-angiogenic vaccine, subsequent to which assessment is made in a patient specific manner of the immune targets that are recognized in response to the immunizing mixture. ... Batu Biologics Inc

Treatment of glioma by anti-angiogenic active immunization for direct tumor inhibition and augmentation of chemotherapy, immunotherapy and radiotherapy efficacy

Disclosed are compositions of matter, therapeutic protocols, and immunization means to induce an active immune response to vasculature feeding glioma or other brain neoplasia. In one embodiment the invention provides administration of placental derived endothelial cells at concentrations of 10 million to 50 million administered in a manner to stimulate immunity toward blood vessels supplying glioma or other brain neoplastic malignancies. ... Batu Biologics Inc

Inhibition of tumor angiogenesis by checkpoint inhibitors and active vaccination

Disclosed are compositions of matter, methods, and protocols useful for treatment of cancer through induction of anti-angiogenic immune responses by vaccination together with immune modulation triggered by checkpoint inhibitors. The invention provides placenta, placental endothelial, placental fibroblasts, and mixtures thereof as immunogens, whose anti-angiogenic activity is augmented by utilization of checkpoint inhibitors. ... Batu Biologics Inc

01/26/17 / #20170021002

Augmentation of cancer and cancer endothelial vaccine immunogenicity by histone deacetylase inhibitors

Disclosed are protocols, procedures and therapeutic compositions useful for augmentation of immunity to cancer and cancer associated endothelial cells by treatment with histone deacetylase (hdac) inhibitors capable of augmenting stimulatory and costimulatory molecules on said cancer vaccines. Additionally, the invention teaches specific concentrations of hdac inhibitors useful for stimulation of in vivo immunity to tumor and tumor endothelial cell targeting vaccines.. ... Batu Biologics Inc

01/26/17 / #20170020922

Gene editing for immunological destruction of neoplasia

Disclosed are methods, protocols, and compositions of matter useful for induction and/or propagation of antitumor immune responses through gene editing of immunocytes. Stimulation of antitumor adaptive immunity is achieved through gene editing of autologous or allogeneic lymphocytes in a manner to derepress neoplasia induced suppression. ... Batu Biologics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Batu Biologics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Batu Biologics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###